---
title: "Astellas Pharma Earnings Up In Q1; Guides FY27"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294924513.md"
description: "Astellas Pharma reported a significant Q1 earnings increase, with net income rising to 141.81 billion yen from 68.42 billion yen the previous year. Revenue also grew to 640.91 billion yen. The company guided for FY27 revenue of 2.22 trillion yen, up 3.8%, and operating profit of 395 billion yen, up 3.2%. Stock closed slightly down at JPY 2,159."
datetime: "2026-08-05T07:13:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294924513.md)
  - [en](https://longbridge.com/en/news/294924513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294924513.md)
generator: "portal-rs"
---

# Astellas Pharma Earnings Up In Q1; Guides FY27

Add  as your preferred news source on Google

 Add Now

Astellas Pharma Inc. (4503.T, ALPMF,ALPMY), a pharmaceutical and life sciences company, on Wednesday reported higher net income in the first quarter compared with the previous year. 

For the first quarter, profit attributable to owners of the parent increased to 141.81 billion yen from 68.42 billion yen in the previous year. 

Earnings per share were 78.96 yen versus 38.11 yen last year. 

Operating profit jumped to 184.51 billion yen from 94.65 billion yen in the prior year. 

Revenue increased to 640.91 billion yen from 505.79 billion yen in the previous year. 

Looking ahead, the company expects fiscal 2027 revenue to increase 3.8% year over year to 2.22 trillion yen. Full-year 2027 operating profit is projected to rise 3.2% to 395 billion yen.

Profit attributable to owners of the parent for fiscal 2027 is expected to increase 2.9% year over year to 300 billion yen, with basic earnings per share projected at 167.46 yen.

Astellas Pharma closed trading 0.44% lesser at JPY 2,159 on the Tokyo Stock Exchange. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [ALPMY.US](https://longbridge.com/en/quote/ALPMY.US.md)
- [4503.JP](https://longbridge.com/en/quote/4503.JP.md)

## Related News & Research

- [Astellas doses first patient in Phase 3 study of ASP2138 for CLDN18.2-positive gastric, GEJ cancer](https://longbridge.com/en/news/296837470.md)
- [Astellas Pharma: Q1 delivered record revenue and profit growth, led by strategic brands and pipeline advances](https://longbridge.com/en/news/294920578.md)
- [Japan debt-servicing cost to rise 17% to record in next fiscal year, Kyodo reports](https://longbridge.com/en/news/296876627.md)
- [Weekly Recap: 70%+ global foundry share and ADR 26.6% above fair value](https://longbridge.com/en/news/296712701.md)
- [Morgan Stanley Initiates ArcelorMittal ADR Coverage at Overweight with $82 Price Target, Highlighting Compelling Valuation Upside](https://longbridge.com/en/news/296764162.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**